Condition: Chlamydia Trachomatis Immunization · Sponsor: Sanofi
The purpose of this study is to evaluate the safety, efficacy, and immunogenicity of different dose levels (low, medium, and high) of Chlamydia messenger ribonucleic acid (mRNA) Vaccine candidate in adult participants aged 18 to 29 years. This study will consist of 3 Sentinel Cohorts and a Main Cohort, with the Sentinel Cohorts assessing the safety of the different dose levels in a stepwise manner. All participants will be followed up to 12 months after the last study intervention administration. Thus, the expected duration of the participant's involvement will be 18 months.
This description comes directly from the study's public registry record.
Trial Transparency email recommended (Toll free for US & Canada) · 800-633-1610 · Contact-US@sanofi.com
Always discuss trial participation with your own doctor first.
| Investigational Site Number : 0360002 | Bruce, Australian Capital Territory, Australia | Recruiting |
| Investigational Site Number : 0360006 | Maroubra, New South Wales, Australia | Recruiting |
| Investigational Site Number : 0360005 | Sydney, New South Wales, Australia | Recruiting |
| Investigational Site Number : 0360001 | Albion, Queensland, Australia | Recruiting |
| Investigational Site Number : 0360004 | Morayfield, Queensland, Australia | Recruiting |
| Investigational Site Number : 0360003 | Southport, Queensland, Australia | Recruiting |
| Investigational Site Number : 0360010 | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06891417